A rapid, selective and sensitive reversed-phase HPLC method for the determination of etodolac in human serum was developed, validated, and applied to the pharmacokinetic study of etodolac. Etodolac and internal standard, ibuprofen were extracted from human serum by liquid-liquid extraction with hexa...
A rapid, selective and sensitive reversed-phase HPLC method for the determination of etodolac in human serum was developed, validated, and applied to the pharmacokinetic study of etodolac. Etodolac and internal standard, ibuprofen were extracted from human serum by liquid-liquid extraction with hexane/isopropanol (95:5, v/v) and analyzed on a Luna C18(2) column with the mobile phase of 1% aqueous acetic acid-acetonitrile (4:6, v/v). Detection wavelength of 227 nm and flow rate of 1.0 mL/min were fixed for the study. The assay robustness for the changes of mobile phase pH, organic solvent content, and flow rate was confirmed by $3^3$ factorial design using a fixed etodolac concentration $(1\;{\mu}g/mL)$ with respect to its peak area and retention time. And also, the ruggedness of this method was investigated at three different laboratories using same quality control (QC) samples. This method showed linear response over the concentration range of $0.05-40\;{\mu}g/mL$ with correlation coefficients greater than 0.999. The lower limit of quantification using 0.5 mL of serum was 0.05 ${\mu}g/mL$, which was sensitive enough for pharmacokinetic studies. The overall accuracy of the quality control samples ranged from 92.00 to 110.00% for etodolac with overall precision (% C.V.) being 1.08-10.11%. The percent recovery for human serum was in the range of 76.73-115.30%. Stability studies showed that etodolac was stable during storage, or during the assay procedure in human serum. The peak area and retention time of etodolac were not significantly affected by the changes of mobile phase pH, organic solvent content, and flow rate under the conditions studied. This method showed good ruggedness (within 15% C.V.) and was successfully used for the analysis of etodolac in human serum samples for the pharmacokinetic studies of orally administered Lodin XL tablet (400 mg as etodolac) at three different laboratories, demonstrating the suitability of the method.
A rapid, selective and sensitive reversed-phase HPLC method for the determination of etodolac in human serum was developed, validated, and applied to the pharmacokinetic study of etodolac. Etodolac and internal standard, ibuprofen were extracted from human serum by liquid-liquid extraction with hexane/isopropanol (95:5, v/v) and analyzed on a Luna C18(2) column with the mobile phase of 1% aqueous acetic acid-acetonitrile (4:6, v/v). Detection wavelength of 227 nm and flow rate of 1.0 mL/min were fixed for the study. The assay robustness for the changes of mobile phase pH, organic solvent content, and flow rate was confirmed by $3^3$ factorial design using a fixed etodolac concentration $(1\;{\mu}g/mL)$ with respect to its peak area and retention time. And also, the ruggedness of this method was investigated at three different laboratories using same quality control (QC) samples. This method showed linear response over the concentration range of $0.05-40\;{\mu}g/mL$ with correlation coefficients greater than 0.999. The lower limit of quantification using 0.5 mL of serum was 0.05 ${\mu}g/mL$, which was sensitive enough for pharmacokinetic studies. The overall accuracy of the quality control samples ranged from 92.00 to 110.00% for etodolac with overall precision (% C.V.) being 1.08-10.11%. The percent recovery for human serum was in the range of 76.73-115.30%. Stability studies showed that etodolac was stable during storage, or during the assay procedure in human serum. The peak area and retention time of etodolac were not significantly affected by the changes of mobile phase pH, organic solvent content, and flow rate under the conditions studied. This method showed good ruggedness (within 15% C.V.) and was successfully used for the analysis of etodolac in human serum samples for the pharmacokinetic studies of orally administered Lodin XL tablet (400 mg as etodolac) at three different laboratories, demonstrating the suitability of the method.
R. Rothstein, Safety profiles of leading nonsteroidal anti-inflammatory drugs, Am. J. Med., 105(5A), 39-43S (1998)
J.P. Boni, J.M. Korth-Bradley, P. Martin, D.K. Simcoe, L.S. Richards, R. Rennebohm and P.D. Walson, Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis, Clin. Ther., 21(10), 1715-1724 (1999)
Martindale, The complete drug reference, 32 editions 1999, p. 32 (1999)
식품의약품안전청 고시 제 2002-60호, 생물학적동등성시험기준 (2002. 11. 22)
M.R. Koupai-Abyazani, B. Esaw and B. Laviolette, Etodolac in equine urine and detection, confirmation, and metabolite identification by atmospheric pressure ionization mass spectrometry, J. Toxicology, 23(3), 200-209 (1999)
L. Cosyns, M. Spain and M. Kraml, Sensitive high-performance liquid chromatographic method for the determination of etodolac in serum, J. Pharm. Sci., 72(3), 275-277 (1983)
U. Becker-Scharfenkamp and G. Blaschke, Evaluation of the stereoselective metabolism of the chiral analgesic drug etodolac by high-performance liquid chromatography, J. Chromatogr., 621(2), 199-207 (1993)
Y.J. Lee, S.J. Chung and C.K. Shim, Bioavailability Analysis Program BA Calc. 2002 for Windows, Ver. 1.1.1, Seoul National University, Seoul, Korea (2002)
WinNonlinTM Users Guide Ver. 3.0, Pharsight Corp. Mountain View, CA, USA (1998-1999)
AI-Helper
※ AI-Helper는 부적절한 답변을 할 수 있습니다.